ABBV·Healthcare·Dividend Aristocrats
AbbVie Earnings +4.5% Surge After Bullish Upgrade Shock
Are AbbVie Earnings and a surprise Bank of America upgrade signaling a new phase in the pharma giant’s post-Humira transition?…
Healthcare
ABBV·Healthcare·Dividend Aristocrats
LLY·Healthcare·Pharma
Eli Lilly Earnings Soar 156% as GLP‑1 Boom Lifts Outlook
Are Eli Lilly earnings finally proving that the GLP‑1 obesity boom can justify today’s sky‑high valuation? Maik Kemper Editor in…
GEHC·Healthcare
GE HealthCare Earnings Shock After Q1 Miss and Outlook Cut
Are GE HealthCare Earnings flashing a temporary warning sign or the start of a deeper rerating for this medtech heavyweight?…
LLY·Healthcare·Pharma
Eli Lilly Earnings Surge 56% as Stock Soars 8.3%
Can Eli Lilly’s explosive GLP-1 demand and raised outlook really justify one of the richest valuations in global pharma? Maik…
LLY·Healthcare·Pharma
Eli Lilly Acquisition Boom: $2.3B Ajax Oncology Shock
Is the latest Eli Lilly Acquisition of Ajax Therapeutics a smart oncology pivot or a risky $2.3 billion side bet?…
TMO·Healthcare
Thermo Fisher Earnings: -10% Stock Plunge After Outlook Hike
Can upbeat Thermo Fisher earnings and a higher 2026 outlook really justify a double-digit stock plunge on weak organic growth?…
WAY·Healthcare
Wayfair News Analysis -2.0%: Plunge Warning for Bulls
Is Wayfair’s latest slide just noise or a fresh warning shot for investors betting on an e-commerce turnaround? Maik Kemper…
ISRG·Healthcare·Pharma
Intuitive Surgical Earnings +23% Surge: Can the Rally Last?
Can blockbuster Intuitive Surgical Earnings and a sharp stock surge finally silence the skeptics circling robotic surgery growth? Maik Kemper…
UNH·Healthcare
UnitedHealth Earnings Q1 Beat as AI Spend Surges
Are stronger UnitedHealth Earnings and a billion‑dollar AI push enough to turn last year’s turmoil into a durable 2026 comeback?…
LLY·Healthcare·Pharma
Eli Lilly Acquisition Boom: Multi‑Billion Cancer and Obesity Bet
Can the latest Eli Lilly Acquisition in next‑gen cancer therapy really justify its sky‑high valuation beyond the obesity drug boom?…